Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Heidelberg Pharma stock

HPHA.DE
DE000A11QVV0
A11QVV

Price

2.35
Today +/-
-0.10
Today %
-4.17 %

Heidelberg Pharma stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Heidelberg Pharma stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Heidelberg Pharma stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Heidelberg Pharma stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Heidelberg Pharma's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Heidelberg Pharma Stock Price History

DateHeidelberg Pharma Price
12/3/20242.35 undefined
12/2/20242.45 undefined
11/29/20242.40 undefined
11/28/20242.38 undefined
11/27/20242.27 undefined
11/26/20242.29 undefined
11/25/20242.19 undefined
11/22/20242.23 undefined
11/21/20242.17 undefined
11/20/20242.24 undefined
11/19/20242.26 undefined
11/18/20242.28 undefined
11/15/20242.28 undefined
11/14/20242.34 undefined
11/13/20242.44 undefined
11/12/20242.45 undefined
11/11/20242.26 undefined
11/8/20242.41 undefined
11/7/20242.40 undefined
11/6/20242.54 undefined
11/5/20242.52 undefined
11/4/20242.52 undefined

Heidelberg Pharma Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Heidelberg Pharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Heidelberg Pharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Heidelberg Pharma’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Heidelberg Pharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Heidelberg Pharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Heidelberg Pharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Heidelberg Pharma’s growth potential.

Heidelberg Pharma Revenue, EBIT and net profit per share

DateHeidelberg Pharma RevenueHeidelberg Pharma EBITHeidelberg Pharma Net Income
2026e13.26 M undefined-39.78 M undefined-39.93 M undefined
2025e9.18 M undefined-32.33 M undefined-35.89 M undefined
2024e10.2 M undefined-25.3 M undefined-20.44 M undefined
20239.86 M undefined-21.3 M undefined-20.35 M undefined
202218.51 M undefined-18.26 M undefined-19.7 M undefined
20211.75 M undefined-25.93 M undefined-26.14 M undefined
20208.49 M undefined-18.52 M undefined-18.37 M undefined
20197.31 M undefined-10.37 M undefined-10.15 M undefined
20183.67 M undefined-11.94 M undefined-11.67 M undefined
20171.9 M undefined-10.86 M undefined-10.97 M undefined
20161.36 M undefined-6.58 M undefined-6.39 M undefined
20152.28 M undefined-6.6 M undefined-6.55 M undefined

Heidelberg Pharma Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2015201620172018201920202021202220232024e2025e2026e
211378118910913
--50.00-200.00133.3314.29-87.501,700.00-50.0011.11-10.0044.44
50.00600.00600.0033.3342.8625.00-200.0072.2266.6760.0066.6746.15
100132-2136000
-6-6-10-11-10-18-26-19-20-20-35-39
--66.6710.00-9.0980.0044.44-26.925.26-75.0011.43
9.1812.4914.3728.2128.2129.932.537.2446.6000
------------
Details

Keystats

ⓘ

Revenue and Growth

The Heidelberg Pharma Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Heidelberg Pharma is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (k)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (k)LONG-T. REC. (k)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (k)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201520162017201820192020202120222023
                 
1.314.5730.3819.449.884.986.1481.3343.44
0.370.090.230.371.231.191.021.10.98
0.090.090.260.250.180.320.430.351.35
0.280.190.180.180.240.230.754.5910.49
22.4541.89154.9456.0363.89798.95676.28513.34382.7
2.074.9931.2120.2911.597.529.0187.8856.63
0.991.271.31.952.433.113.673.723.85
000012.60000
5515352535303030970
2.872.842.822.82.82.822.92.842.79
6.116.116.116.116.116.116.116.116.11
14.9816.3516.3516.359.914.94.94.94.82
10.0310.2510.2810.911.412.0912.7212.713.72
12.115.2441.4931.1922.9919.6121.73100.5870.35
                 
9.3112.9322.4528.1328.2131.0634.1846.5846.6
184.57187.54216.12210.44210.36221.9238.05304.74304.78
-184.4-190.71-201.55-212.69-222.28-240.08-265.53-284.68-302.04
000000000
000000000
9.489.7637.0225.8916.2912.886.766.6449.34
0.280.131.50.411.012.810.93.057.88
1.71.11.73.33.453.462.983.991.17
0.640.51.261.620.250.495.024.97
03.75000010.4715.795.65
00000100.6591.0894.44113.19
2.625.484.465.316.466.6314.9327.9319.78
00000102.0375.57100.3870.41
000000000
0.010.010.0100.2400.025.91.17
0.010.010.0100.240.10.161.24
2.625.494.475.316.76.7315.0333.9421.01
12.115.2441.4931.1922.9919.6121.73100.5870.35
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Heidelberg Pharma provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Heidelberg Pharma's financial health and stability.

Assets

Heidelberg Pharma's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Heidelberg Pharma must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Heidelberg Pharma after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Heidelberg Pharma's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20152016201720182019202020212022
-6-6-10-11-10-18-26-19
00000000
00000000
00200-1-29
20000010
00000000
00000000
-4-6-7-9-8-17-26-8
000-10-1-10
000-10-1-10
00000000
00000000
031400094
462000142079
4103400142984
---1.00-----
00000000
0325-10-9-4175
-5-7.07-8.36-10.98-9.52-19.33-28-9.48
00000000

Heidelberg Pharma stock margins

The Heidelberg Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Heidelberg Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Heidelberg Pharma.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Heidelberg Pharma's sales revenue. A higher gross margin percentage indicates that the Heidelberg Pharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Heidelberg Pharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Heidelberg Pharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Heidelberg Pharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Heidelberg Pharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Heidelberg Pharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Heidelberg Pharma Margin History

Heidelberg Pharma Gross marginHeidelberg Pharma Profit marginHeidelberg Pharma EBIT marginHeidelberg Pharma Profit margin
2026e67.01 %-300 %-301.11 %
2025e67.01 %-352.22 %-390.93 %
2024e67.01 %-248 %-200.38 %
202367.01 %-216.07 %-206.38 %
202274.73 %-98.63 %-106.42 %
2021-169.29 %-1,482.09 %-1,493.79 %
202034.03 %-218.14 %-216.41 %
201948.85 %-141.83 %-138.84 %
201839.8 %-325.67 %-318.23 %
201749.65 %-571.78 %-577.33 %
201640.6 %-483.14 %-469.04 %
201550.09 %-288.79 %-286.87 %

Heidelberg Pharma Stock Sales Revenue, EBIT, Earnings per Share

The Heidelberg Pharma earnings per share therefore indicates how much revenue Heidelberg Pharma has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Heidelberg Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Heidelberg Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Heidelberg Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Heidelberg Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Heidelberg Pharma Revenue, EBIT and net profit per share

DateHeidelberg Pharma Sales per ShareHeidelberg Pharma EBIT per shareHeidelberg Pharma Earnings per Share
2026e0.28 undefined0 undefined-0.86 undefined
2025e0.2 undefined0 undefined-0.77 undefined
2024e0.22 undefined0 undefined-0.44 undefined
20230.21 undefined-0.46 undefined-0.44 undefined
20220.5 undefined-0.49 undefined-0.53 undefined
20210.05 undefined-0.8 undefined-0.8 undefined
20200.28 undefined-0.62 undefined-0.61 undefined
20190.26 undefined-0.37 undefined-0.36 undefined
20180.13 undefined-0.42 undefined-0.41 undefined
20170.13 undefined-0.76 undefined-0.76 undefined
20160.11 undefined-0.53 undefined-0.51 undefined
20150.25 undefined-0.72 undefined-0.71 undefined

Heidelberg Pharma business model

Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany. The company was founded in 1998 and currently employs about 100 employees. Heidelberg Pharma's business model focuses on discovering and developing novel cancer therapies based on antibody-drug conjugates (ADCs). The foundation of Heidelberg Pharma's work lies in research and development in the field of cancer immunotherapy. The company has invested a lot in recent years to develop a wide range of ADCs and test them in clinical trials. The goal of the company is to develop novel therapies that can be used in the fight against cancer. Heidelberg Pharma has three different divisions: the research and development department, the subsidiary Heidelberg Pharma Research GmbH, and the subsidiary Heidelberg Pharma Development GmbH. The research and development department works on innovative technologies and drugs to combat cancer. Both established and novel approaches are used to achieve high efficacy while maintaining tolerability. The subsidiary Heidelberg Pharma Research GmbH is dedicated to developing new ADC therapy approaches, particularly in collaboration with partners. This includes the production and quality control of ADCs as well as the conduct of preclinical studies. On the other hand, the subsidiary Heidelberg Pharma Development GmbH specializes in clinical development and is responsible for the preparation and conduct of clinical trials. Heidelberg Pharma's products mainly include cancer therapies based on ADCs. One such ADC is the product HDP-101, which is currently in Phase I clinical trials. The drug is a better-tolerated successor to the well-known drug doxorubicin, which targets the tumor in combination with a specific antibody. The aim is to effectively destroy the tumor without damaging the healthy cells in the body. Another product in Heidelberg Pharma's pipeline is the ADC HDP-102, which is also being tested in Phase I clinical trials. This is a treatment option specifically intended for the malignant blood disorder multiple myeloma. In addition to developing its own products, Heidelberg Pharma also collaborates closely with partners to develop innovative ADCs. The goal is to provide new therapies as quickly as possible and thus win the fight against cancer. In recent years, Heidelberg Pharma AG has made significant progress and established itself as one of the leading biotechnology companies in the field of cancer research. The company places special emphasis on quality, efficiency, and innovation. Based on its experiences and progress, Heidelberg Pharma plans to remain a leader in the field of cancer research and therapies and further strengthen its position in the industry. Heidelberg Pharma is one of the most popular companies on Eulerpool.com.

Heidelberg Pharma SWOT Analysis

Strengths

Heidelberg Pharma AG possesses several strengths that contribute to its competitive advantage in the market:

  • Strong Research and Development Capabilities: The company has a robust R&D department focused on developing innovative therapeutic solutions.
  • Advanced Technology: Heidelberg Pharma utilizes state-of-the-art technology to enhance drug discovery and development processes.
  • Strong Intellectual Property Portfolio: The company holds a significant number of patents and licenses, providing a competitive edge.
  • Strategic Partnerships: Heidelberg Pharma has established collaborations with key industry players, enabling access to additional expertise and resources.
  • Experienced Management Team: The company is led by a team of seasoned executives with extensive industry knowledge and experience.

Weaknesses

Despite its strengths, Heidelberg Pharma AG faces certain weaknesses that may hinder its performance and growth:

  • Limited Financial Resources: The company's financial resources may be constrained, impacting its ability to invest in research and development initiatives.
  • Dependency on Collaborations: Heidelberg Pharma relies heavily on strategic partnerships, which may introduce risks and uncertainties into its operations.
  • Relatively Small Market Share: The company operates in a highly competitive market, and its current market share is relatively small compared to larger pharmaceutical companies.
  • Lack of Diversification: Heidelberg Pharma's product portfolio is focused on a specific area, limiting the company's exposure to other potential market segments.

Opportunities

Heidelberg Pharma AG can capitalize on the following opportunities to drive future growth and success:

  • Expanding Therapeutic Areas: The company can explore new therapeutic areas and diversify its product portfolio to target a wider patient population.
  • Continued Technological Advancements: Ongoing advancements in technology present opportunities for Heidelberg Pharma to improve its research and development processes.
  • Emerging Markets: The company can focus on expanding its presence in emerging markets where there is growing demand for innovative pharmaceutical solutions.
  • Increasing Focus on Personalized Medicine: Heidelberg Pharma can leverage its expertise in precision medicine and tailor treatments to individual patient needs.

Threats

Heidelberg Pharma AG should be wary of the following threats that may pose challenges to its business:

  • Intense Competition: The pharmaceutical industry is highly competitive, and Heidelberg Pharma faces competition from both established and emerging players.
  • Stringent Regulatory Environment: Compliance with stringent regulations and increasing regulatory scrutiny in the industry can create obstacles and delays.
  • Technological Obsolescence: Rapid advancements in technology may render existing solutions obsolete, requiring continuous innovation to stay competitive.
  • Market Volatility: Fluctuations in the global economy and financial markets can impact Heidelberg Pharma's business operations and financial performance.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Heidelberg Pharma Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Heidelberg Pharma historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Heidelberg Pharma shares outstanding

The number of shares was Heidelberg Pharma in 2023 — This indicates how many shares 46.596 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Heidelberg Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Heidelberg Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Heidelberg Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Heidelberg Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Heidelberg Pharma.

Heidelberg Pharma latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/2011-1.35 -1.19  (11.63 %)2011 Q1
12/31/2010-1.52 -1.19  (21.57 %)2010 Q4
9/30/2010-1.29 -1.23  (4.85 %)2010 Q3
6/30/2010-1.57 -1.42  (8.96 %)2010 Q2
3/31/2010-1.47 -1.24  (15.61 %)2010 Q1
12/31/2009-0.45 -0.46  (-2.13 %)2009 Q4
9/30/2009-0.25 -0.18  (29.97 %)2009 Q3
6/30/2009-1.33 -1.2  (9.91 %)2009 Q2
3/31/2009-1.55 -1.69  (-9.44 %)2009 Q1
12/31/2008-1.69 -1.15  (31.79 %)2008 Q4
1
2

Heidelberg Pharma shareholders

%
Name
Stocks
Change
Date
45.64888 % Hopp (Dietmar)21,272,88109/25/2024
34.98750 % China Grand Enterprises, Inc.16,304,56009/25/2024
0.54230 % NFS Netfonds Financial Service GmbH252,7171427/31/2024
0.45870 % Polar Capital LLP213,760-681,9656/30/2024
0.00730 % Gutmann Finanz Strategien AG3,400-3,0003/31/2024
0 % PVV Private VermögensVerwaltung AG0-25,0003/31/2024
0 % Financi¿re Arbevel0-13,4006/30/2023
1

Heidelberg Pharma Executives and Management Board

Dr. Jan Schmidt-Brand

Heidelberg Pharma Chief Executive Officer, Chief Financial Officer, Member of the Executive Management Board
Compensation 474,360

Prof. Dr. Andreas Pahl

Heidelberg Pharma Chief Scientific Officer, Member of the Executive Management Board
Compensation 441,866

Prof. Dr. Christof Hettich

Heidelberg Pharma Chairman of the Supervisory Board (since 2010)
Compensation 54,000

Dr. Georg Baur

Heidelberg Pharma Deputy Chairman of the Supervisory Board (since 2010)
Compensation 39,500

Prof. Dr. Friedrich Von Bohlen Und Halbach

(62)
Heidelberg Pharma Member of the Supervisory Board
Compensation 30,833
1
2

Heidelberg Pharma Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Nordic Nanovector Stock
Nordic Nanovector
SupplierCustomer0,240,050,410,140,470,30
RedHill Biopharma Ltd ADR Stock
RedHill Biopharma Ltd ADR
SupplierCustomer0,160,570,27-0,130,820,20
Telix Pharmaceuticals Stock
Telix Pharmaceuticals
SupplierCustomer-0,100,420,07-0,37-0,090,31
Magenta Therapeu Stock
Magenta Therapeu
SupplierCustomer-0,150,540,09-0,110,780,61
Takeda Pharmaceutical Stock
Takeda Pharmaceutical
SupplierCustomer-0,27-0,370,060,230,500,18
Dishman Carbogen Amcis Stock
Dishman Carbogen Amcis
SupplierCustomer-0,420,230,42-0,100,21-0,14
1

Most common questions regarding Heidelberg Pharma

What values and corporate philosophy does Heidelberg Pharma represent?

Heidelberg Pharma AG represents core values of innovation, excellence, and integrity in the pharmaceutical industry. With a strong corporate philosophy, the company focuses on developing innovative therapies for the treatment of cancer and other diseases. Heidelberg Pharma AG is committed to advancing scientific research and utilizing cutting-edge technologies to discover and develop novel therapeutic solutions. By prioritizing collaboration and partnership, the company aims to foster sustainable growth and bring transformative therapies to patients worldwide. Heidelberg Pharma AG's corporate philosophy underscores its dedication to improving patient outcomes and driving advancements in the field of oncology.

In which countries and regions is Heidelberg Pharma primarily present?

Heidelberg Pharma AG is primarily present in Germany and Europe.

What significant milestones has the company Heidelberg Pharma achieved?

Heidelberg Pharma AG has achieved several significant milestones. The company successfully developed its proprietary technology platform, Antibody Targeted Amanitin Conjugates (ATAC), which enables the targeted delivery of potent anti-cancer drugs to tumor cells. They have also entered into important strategic partnerships, including collaborations with big pharmaceutical companies, for the development and commercialization of their drug candidates. Additionally, Heidelberg Pharma AG has successfully completed preclinical and clinical studies, demonstrating the potential effectiveness and safety of their ATAC compounds in treating various types of cancers. These milestones highlight the company's commitment to innovation and its potential to make a significant impact in the field of oncology.

What is the history and background of the company Heidelberg Pharma?

Heidelberg Pharma AG is a German biopharmaceutical company specializing in the development of innovative therapeutic drugs for various cancers. Founded in 1997, the company has a rich history of research, collaborations, and breakthrough discoveries. Over the years, Heidelberg Pharma AG has become a leader in the field of antibody-drug conjugates (ADCs), a cutting-edge technology that allows targeted delivery of potent anti-cancer agents to tumor cells. By utilizing their proprietary technology platform, the company aims to develop safer and more effective treatments for patients with unmet medical needs. Heidelberg Pharma AG continues to grow and advance its pipeline, working towards revolutionizing cancer care worldwide.

Who are the main competitors of Heidelberg Pharma in the market?

The main competitors of Heidelberg Pharma AG in the market are companies such as Celgene Corporation, Gilead Sciences Inc., and Johnson & Johnson. These pharmaceutical companies operate in the same industry as Heidelberg Pharma AG and offer similar products and services. Competitor analysis plays a crucial role in the strategic planning and decision-making process for Heidelberg Pharma AG to maintain its competitive edge and market share.

In which industries is Heidelberg Pharma primarily active?

Heidelberg Pharma AG is primarily active in the pharmaceutical industry.

What is the business model of Heidelberg Pharma?

The business model of Heidelberg Pharma AG is focused on developing innovative antibody-based therapies for oncology. The company utilizes its proprietary technology platform, called Antibody Targeted Amanitin Conjugate (ATAC), which combines the specificity of antibodies with the potency of Amanitin, a toxin found in the death cap mushroom. This approach targets cancer cells more effectively while sparing healthy tissue, leading to improved efficacy and reduced side effects. Heidelberg Pharma AG collaborates with pharmaceutical companies to develop and commercialize ATAC candidates. By leveraging its expertise in drug discovery and development, the company aims to provide novel and targeted treatments for cancer patients worldwide.

What is the P/E ratio of Heidelberg Pharma 2024?

The Heidelberg Pharma P/E ratio is -5.36.

What is the P/S ratio of Heidelberg Pharma 2024?

The Heidelberg Pharma P/S ratio is 10.74.

What is the Quality Investing of Heidelberg Pharma?

The Quality Investing for Heidelberg Pharma is 2/10.

What is the revenue of Heidelberg Pharma 2024?

The expected Heidelberg Pharma revenue is 10.2 M EUR.

How high is the profit of Heidelberg Pharma 2024?

The expected Heidelberg Pharma profit is -20.44 M EUR.

What is the business model of Heidelberg Pharma

Heidelberg Pharma AG is a company specialized in the research and development of cancer therapies in the biotechnology industry. Its business model is based on the use of its own ADC technology platform (Antibody-Drug Conjugates) for the identification and development of new cancer drugs. The company operates in two main business areas: pharmaceutical research and clinical development. In pharmaceutical research, the focus is on identifying and validating new target proteins for cancer drugs using advanced methods of genetics, proteomics, and cell biology. In clinical development, the company concentrates on developing cancer drugs using its ADC technology platform. ADCs consist of an antibody that selectively binds to the desired target protein in the tumor, and a chemical drug. Once the antibody recognizes the target protein, the drug is activated and destroys the cancer cell. This ensures that the drug is released only in the tumor and spares healthy cells. Heidelberg Pharma has an extensive portfolio of ADCs currently in various phases of clinical studies, including the drug HDP-101 for the treatment of various solid tumors. The company also addresses other types of cancer such as multiple myeloma, lung cancer, and pancreatic cancer. Its business model is based on the complete control of its ADC technology platform, as well as the extensive experience and know-how built in cancer research and drug development. Strategic licensing and cooperation partnerships are used to advance the development of its cancer drugs, aiming to achieve efficiency gains and reduce product failure risks. Overall, Heidelberg Pharma's business model is characterized by a strong and efficient ADC technology platform, extensive experience in cancer research, successful clinical developments, and strategic partnerships. All of these factors will contribute to the company's future growth and establishment as a significant player in cancer treatment.

What is the Heidelberg Pharma dividend?

Heidelberg Pharma pays a dividend of 0 EUR distributed over payouts per year.

How often does Heidelberg Pharma pay dividends?

The dividend cannot currently be calculated for Heidelberg Pharma or the company does not pay out a dividend.

What is the Heidelberg Pharma ISIN?

The ISIN of Heidelberg Pharma is DE000A11QVV0.

What is the Heidelberg Pharma WKN?

The WKN of Heidelberg Pharma is A11QVV.

What is the Heidelberg Pharma ticker?

The ticker of Heidelberg Pharma is HPHA.DE.

How much dividend does Heidelberg Pharma pay?

Over the past 12 months, Heidelberg Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Heidelberg Pharma is expected to pay a dividend of 0 EUR.

What is the dividend yield of Heidelberg Pharma?

The current dividend yield of Heidelberg Pharma is .

When does Heidelberg Pharma pay dividends?

Heidelberg Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Heidelberg Pharma?

Heidelberg Pharma paid dividends every year for the past 0 years.

What is the dividend of Heidelberg Pharma?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Heidelberg Pharma located?

Heidelberg Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Heidelberg Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Heidelberg Pharma from 12/3/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 12/3/2024.

When did Heidelberg Pharma pay the last dividend?

The last dividend was paid out on 12/3/2024.

What was the dividend of Heidelberg Pharma in the year 2023?

In the year 2023, Heidelberg Pharma distributed 0 EUR as dividends.

In which currency does Heidelberg Pharma pay out the dividend?

The dividends of Heidelberg Pharma are distributed in EUR.

All fundamentals about Heidelberg Pharma

Our stock analysis for Heidelberg Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Heidelberg Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.